<DOC>
	<DOCNO>NCT02527863</DOCNO>
	<brief_summary>Tolvaptan selective vasopressin receptor antagonist ( V2R ) increase free water sodium excretion . Inhibition V2R increase vasopressin concentration plasma , stimulate V1-receptors vascular bed may change central brachial hemodynamics plasma concentration vasoactive hormone . The purpose study measure effect tolvaptan renal handling water sodium , systemic hemodynamics vasoactive hormone baseline nitric oxide ( NO ) -inhibition L-NG-monomethyl-arginine ( L-NMMA ) patient autosomal dominant polycystic kidney disease .</brief_summary>
	<brief_title>Effect Aquaretic Tolvaptan Nitric Oxide System</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney , Autosomal Dominant</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<criteria>1 . Caucasian men woman 2 . Age 1865 year 3 . ADPKD , diagnose genetic testing PKD1 ( &gt; 85 % ) PKD2 mutation , ultrasonography : 1. patient negative family history ADKPD 10 cyst kidney extrarenal renal finding suggest cause cyst formation . 2. patient positive family history ADPKD : 1539 yr age least 3 unilateral bilateral . 4059 yr age 2 cyst kidney . 60 yr age least 4 cyst kidney . 4 . Kidney function correspond CKD stage 13 ( eGFR &gt; 30 mL/min/1,73 m2 ) , 5 . BMI 18.5 35.5 kg/m2 . 1 . Clinical sign diseases heart , lung , endocrine organ , brain neoplastic disease , 2. clinically significant abnormality blood urine sample inclusion 3. previous cerebrovascular insult , 4. previous clinical evidence aneurysm 5 . Alcohol drug abuse , 6. smoking , 7. pregnancy breastfeeding , 8. clinically significant change electrocardiogram , 9. medication except antihypertensive agent oral contraceptive , 10. blood pressure &gt; 170/105 mmHg despite treatment metoprolol and/or amlodipine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Tolvaptan</keyword>
	<keyword>L-NMMA</keyword>
	<keyword>ADPKD</keyword>
</DOC>